FINA BIOTECH (acquiring company) has recently completed its merger by absorption with BIOFINA DIAGNOSTICS (acquired company). Both companies took the decision in their respective shareholders´ meeting last June. The combination amplifies FINA BIOTECH´s expertise and capabilities and allows it to better and more efficiently achieve its strategic goal of taking to the market UROBEST®, a non-invasive method for the diagnosis of bladder cancer, based on the combination of genetic markers of the disease.
Fina Biotech S.L. (www.finabiotech.es) is a spin-off of Laboratorios Indas (www.indas.com), with a strong pipeline of biotechnology projects and a proven track record in product development. Fina Biotech has invested close to €12 million in 28 projects in the diagnostics and cell therapy fields, most of them in partnership with public and private institutions, laboratories and universities. A product developed by Fina Biotech, a diagnostic test for male infertility (Halosperm®) is already marketed. A bladder cancer diagnostic test based on RT-qPCR technology has already been validated in clinical studies and has proven to have better sensitivity and specificity than other available diagnostic tests .
Biofina Diagnostics S.L. (www.biofinadx.com) is born to further develop and take the bladder cancer diagnostic test to the market. The company holds the exclusive exploitation and commercialization rights on Fina Biotech´s patents protecting UROBEST®.
